False
September 30, 2026
How direct T-cell reprogramming could simplify CAR-T manufacturing, expand patient access, and extend cellular immunotherapy to new indications
10 min read
September 30, 2026
Fayuvi is authorized for pediatric patients with preserved neurodevelopmental function following a study comparing treated children with a natural history cohort
2 min read
September 29, 2026
Coordinated development and practical testing pathways can help ensure eligible patients are identified from the point of approval
5 min read
September 28, 2026
Phase I study will test whether a targeted lentiviral vector can generate BCMA-directed CAR T cells inside patients with multiple myeloma
3 min read
September 28, 2026
Renee Aguiar-Lucander argues that faster clinical trials and more pragmatic regulation are essential to bringing medicines to patients sooner
2 min read
September 25, 2026
IBTV speaks with industry leaders at ASGCT 2026 about the regulatory, manufacturing, investment, and commercialization trends signaling a new phase for advanced therapies
1 min read
September 24, 2026
Trametinib and dabrafenib increased TSHR expression and improved the activity of CAR T cells in a patient-derived model of anaplastic thyroid cancer
2 min read
September 23, 2026
Scientific breakthroughs are only true innovations if healthcare systems can deliver them safely, manage their toxicities, and make them accessible at scale
6 min read
September 23, 2026
Meditope-enabled CAR T cells can be tracked, selectively expanded, and directed toward additional tumor antigens using externally administered protein adaptors
2 min read
September 22, 2026
CCRM CEO Michael May on quantum computing, commercialization, and the next era of cell therapy
5 min read
False